Stockscreener 앱 받기
1.09
0.00%
0.00
전일 마감가:
$1.09
열려 있는:
$1.09
하루 거래량:
1.54M
Relative Volume:
1.04
시가총액:
$97.55M
수익:
-
순이익/손실:
$-19.58M
주가수익비율:
-4.2297
EPS:
-0.2577
순현금흐름:
$-20.25M
1주 성능:
-6.84%
1개월 성능:
-4.39%
6개월 성능:
-22.70%
1년 성능:
+55.78%
1일 변동 폭
$1.04
$1.105
1주일 범위
$1.00
$1.175
52주 변동 폭
$0.5501
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.09 | 97.55M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment - Investing.com South Africa
Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in FocusTrading Ideas - dars.gov.et
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo
Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index - marketscreener.com
Cognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33% - MSN
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Index - marketscreener.com
Cognition, FDA agree on late-stage trial for dementia therapy - MSN
symbol__ Stock Quote Price and Forecast - CNN
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain - Seeking Alpha
CGTX Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Rises on Progress in Alzheimer's Pipeline - dars.gov.et
Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX) - TradingView
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
CGTX Forecast — Price Target — Prediction for 2027 - TradingView
Cognition Therapeutics | 10-K: FY2025 Annual Report - Moomoo
FDA says DLB psychosis could be approvable in Cognition trial plan - Stock Titan
Cognition Therapeutics receives FDA alignment on Phase 3 trial of zervimesine for DLB psychosis - grafa.com
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% - TradingView
Cognition Therapeutics Secures FDA Alignment for Pivotal Phase 3 Trial of Zervimesine in DLB Psychosis, Targeting First Durable Treatment Option 1 – Minichart - Minichart
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) - Yahoo Finance
Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment - marketscreener.com
Cognition Therapeutics stock rises on FDA trial alignment By Investing.com - Investing.com Canada
Cognition Therapeutics aligned with FDA on pivotal Phase 3 design for zervimesine in DLB psychosis - TradingView
Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis - Quiver Quantitative
Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine - Stock Titan
Cognition Therapeutics Aligns on Key Aspects of Pivotal - GlobeNewswire
Form DEF 14A Cognition Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Form 4 Cognition Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Cognition Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Khattar Jack A. - Moomoo
Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs - Stock Titan
Director at Cognition Therapeutics (CGTX) receives 25,000 RSUs and holds 73,500 shares - Stock Titan
RSU grant lifts Cognition Therapeutics (CGTX) director Peggy Wallace’s holdings - Stock Titan
Cognition Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wallace Peggy - Moomoo
Director at Cognition Therapeutics (CGTX) granted 25,000 RSUs - Stock Titan
[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity - Stock Titan
H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news - Investing.com
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor - The Globe and Mail
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial - TipRanks
Cognition Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com UK
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):